Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis

Marks, Robert D.; Richter, Joel E.; Rizzo, John A.; Koehler, Robert E.; Spenney, Jerry G.; Mills, Thomas P.; Champion, Gregory

doi:10.1016/0016-5085(94)90749-8

Cited by 212 publications

(78 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A stricture elsewhere should raise suspicion for another etiology. PPIs are clearly superior to H 2 -receptor antagonists and when used in a maintenance fashion improve dysphagia, decrease the need for repetitive dilations and / or prolong the interval between dilations ( 171,172 ).…”

Section: Summary Of the Evidencementioning

confidence: 99%

Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease

Katz¹,

Gerson²,

Vela³

2013

American Journal of Gastroenterology

1,533

1,430

View full text Add to dashboard Cite

Section: Summary Of the Evidencementioning

confidence: 99%

Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease

Katz¹,

Gerson²,

Vela³

2013

American Journal of Gastroenterology

1,533

1,430

View full text Add to dashboard Cite

“…For example, acid suppression has also been shown to effectively prevent the recurrence of erosive oesophagitis and/or oesophageal strictures. [18][19] Anecdotal observations also indicate that the incidence of new oesophageal peptic strictures is declining in recent times. In a study of patients with normalization of intraoesophageal pH, acid suppression has been shown to decrease markers of cellular proliferation, e.g.…”

Section: Discussionmentioning

confidence: 99%

The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy

El–Serag

Aguirre

Kuebeler

et al. 2004

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background : The length of Barrett's oesophagus seems to correlate well with indicators of severe gastro‐oesophageal reflux disease. However, it remains unknown whether prior acid suppressive therapy affects the length of newly diagnosed Barrett's oesophagus. Methods : A retrospective analysis of a well‐characterized large cohort of patients with Barrett's oesophagus diagnosed between 1981 and 2000. Aim : To compare the length of Barrett's oesophagus between patients who received acid suppressive therapy prior to their diagnosis to those who did not receive such therapy. Pharmacy records were obtained from Department of the Veterans Affairs computerized records and prospectively collected research records. We further examined the association between prior use of acid suppressive therapy and the length of Barrett's oesophagus in correlation analyses, as well as multivariate linear regression analyses while adjusting for differences in year of diagnosis, age, gender, ethnicity, and the presence of intestinal metaplasia of the gastric cardia. Results : There were 340 patients with Barrett's oesophagus first diagnosed between 1981 and 2000. The average length of Barrett's oesophagus at the time of first diagnosis was 4.4 cm (range: 0.5–16). Of all patients, 139 (41%) had prior use of histamine‐2 receptor antagonists, or proton‐pump inhibitors (41 used both), and 201 (59%) used neither prior to the diagnosis of Barrett's oesophagus. The mean length of Barrett's oesophagus was significantly shorter in patients with prior use of proton‐pump inhibitors (3.4 cm) or proton‐pump inhibitors and histamine‐2 receptor antagonists (3.1 cm) when compared to those with none of these medications (4.8 cm). In the multivariate linear regression model, the prior use of proton‐pump inhibitors or either proton‐pump inhibitors or histamine‐2 receptor antagonists was an independent predictor of shorter length of Barrett's oesophagus (P = 0.0396). Conclusions : The use of acid suppressive therapy among patients is associated with a reduction in the eventual length of newly diagnosed Barrett's oesophagus with gastro‐oesophageal reflux disease. This finding is independent of the year of diagnosis or demographic features of patients. Further studies are required to confirm this finding.

show abstract

“…Cimetidine 400 mg four times a day did not affect the frequency of the need for dilation (88), but several studies have found that fulldose PPIs will lengthen the interval between symptomatic relapses (89,90). There are no similar data in regards to the prevention or prevention of progression of Barrett's esophagus.…”

Section: Because Gerd Is a Chronic Condition Continuous Therapy To Cmentioning

confidence: 99%

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

DeVault¹

1999

The American Journal of Gastroenterology

143

178

View full text Add to dashboard Cite

PREAMBLEGuidelines for the diagnosis and treatment of gastroesophageal reflux disease (GERD) were published by the American College of Gastroenterology in 1995 (1). These and other guidelines undergo periodic review. Significant advances have been made in the area of GERD over the past several years, leading us to review and revise our previous guidelines statements. These advances have included an increase in our comfort with the chronic use of proton pump inhibitors and an increased acceptance of laparoscopic antireflux surgery, among other factors. These and the original guidelines are intended to apply to all physicians who address GERD and are intended to indicate the preferable, but not only acceptable, approach. Physicians must always choose the course best suited to the individual patient and the variables that exist at the moment of the decision. These guidelines are intended to apply to adult patients with the symptoms, tissue damage, or both that result from the reflux of gastric contents into the esophagus. For the purpose of these guidelines GERD is defined as chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus.Both these and the original guidelines were developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee, and approved by the Board of Trustees. The world literature was reviewed extensively for the original guidelines and was once again reviewed using the National Library of Medicine database. All appropriate studies were reviewed and any additional studies found in the reference list of these papers were obtained and reviewed. Evidence was evaluated along a hierarchy, with randomized controlled trials given the greatest weight. Abstracts presented at national and international meetings were only used when unique data from ongoing trials were presented. When scientific data were lacking, recommendations were based on expert consensus. During preparation, the guidelines were reviewed

show abstract

Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis

Cited by 212 publications

References 15 publications

Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease

Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease

The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

Contact Info

Product

Resources

About